A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.
This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.
A large nationwide study in Taiwan found that patients with autoimmune skin diseases had lower all-cause and cancer-specific mortality following cancer treatment compared with those without these conditions.
A recent study reveals significant treatment response improvements in severe psoriatic arthritis and extensive psoriasis, emphasizing the need for personalized treatment strategies and sensitive outcome measures. (Source: Psoriatic Arthritis Research Consortium)
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
French researchers in JAMA Dermatology linked high ultraprocessed food consumption to increased rates of psoriasis, emphasizing the need for further investigation.
A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.